Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies by Mesa, RA, Hudgens, S, Floden, L, Harrison, CN, Palmer, J, Gupta, V, McLornan, DP, McMullin, MF, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, ML, Mead, AJ, Ross, DM, Oh, ST, Perkins, A, Leahy, MF, Deheshi, S, Donahue, R, Klencke, BJ, Verstovsek, S